Advertisement
U.S. markets closed
Advertisement

Genenta Science S.p.A. (GNTA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Visitors trend2W10W9M
5.24+0.29 (+5.86%)
At close: 09:30AM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Performance Outlook
Previous Close4.95
Open5.24
Bid5.01 x 800
Ask7.91 x 900
Day's Range5.20 - 5.24
52 Week Range4.29 - 7.08
Volume1,026
Avg. Volume1,952
Market Cap95.457M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.78
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est23.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for GNTA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Genenta Science S.p.A.
    LGND: What does Argus have to say about LGND?LIGAND PHARMACEUTICALS has an Investment Rating of HOLD; a target price of $61.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of Medium.
    Rating
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • Simply Wall St.

    Individual investors account for 54% of Genenta Science S.p.A.'s (NASDAQ:GNTA) ownership, while insiders account for 30%

    Key Insights Significant control over Genenta Science by individual investors implies that the general public has more...

  • GlobeNewswire

    Genenta to Present at Upcoming Scientific and Investor Conferences

    MILAN, Italy and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ: GNTA) a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells towards a permanent self-vaccination against cancer, will present at several upcoming scientific and investor conferences. H.C. Wainwright 25th Annual Global Investment Conference, September 11-13 2023, NYC-USPresenters: Pierluigi Paracchi, CEO and Co-founder, Carlo Russo, CMO

  • GlobeNewswire

    Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments

    Company Selects Refractory Advanced Genitourinary Malignancies including Renal Cell Cancer as Second IndicationCompany Selects Refractory Advanced Genitourinary Malignancies including Renal Cell Cancer as Second Indication MILAN, Italy and NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology (I/O) company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors